Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L. Spruance SL, et al. Ann Intern Med. 1994 Mar 1;120(5):360-8. doi: 10.7326/0003-4819-120-5-199403010-00002. Ann Intern Med. 1994. PMID: 7905722 Clinical Trial.
A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease.
Shepp DH, Ramirez-Ronda C, Dall L, Pollard RB, Murphy RL, Kessler H, Sherer R, Mertz G, Perez G, Gocke DJ, Greenberg SB, Petersen E, Frank I, Moore MD, McKinnis R, Rooney JF. Shepp DH, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1;15(4):283-8. doi: 10.1097/00042560-199708010-00006. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9292587 Clinical Trial.
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF. Schooley RT, et al. J Infect Dis. 1996 Jun;173(6):1354-66. doi: 10.1093/infdis/173.6.1354. J Infect Dis. 1996. PMID: 8648207 Clinical Trial.
125 results